Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Sihang JiangSchool of Engineering and Applied Science, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0002-0502-6432
Johanna LoombaIntegrated Translational Health Research Institute of Virginia (iTHRIV), University of Virginia, Charlottesville, VA 22903, USA.
Andrea ZhouIntegrated Translational Health Research Institute of Virginia (iTHRIV), University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0003-1845-5620
Suchetha SharmaSchool of Data Science, University of Virginia, Charlottesville, VA 22903, USA.
Saurav SenguptaSchool of Data Science, University of Virginia, Charlottesville, VA 22903, USA.
Jiebei LiuSchool of Engineering and Applied Science, University of Virginia, Charlottesville, VA 22903, USA.
Donald BrownSchool of Data Science, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0002-9140-2632
On Behalf Of N C Consortium
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
Since the outbreak of the COVID-19 pandemic in 2020, numerous studies have focused on the long-term effects of COVID infection. On 1 October 2021, the Centers for Disease Control (CDC) implemented a new code in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) for reporting 'Post COVID-19 condition, unspecified (U09.9)'. This change indicated that the CDC recognized Long COVID as a real illness with associated chronic conditions. The National COVID Cohort Collaborative (N3C) provides researchers with abundant electronic health record (EHR) data by harmonizing EHR data across more than 80 different clinical organizations in the United States. This paper describes the creation of a COVID-positive N3C cohort balanced by the presence or absence of Long COVID (U09.9) and evaluates whether or not documented Long COVID (U09.9) is associated with decreased survival length.
Indexed as
Bayesian survival analysislog-normal modellong COVIDMarkov chain Monte CarloN3C
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Bayesian Survival Analysis on Long COVID and Non-Long COVID Patients: A Cohort Study Using National COVID Cohort Collaborative (N3C) Data. · full record | OpenQuestion